OMS302-PE · Ketorolac Tromethamine, Omidria

What is OMS302-PE?

Omidria is a combination of phenylephrine and ketorolac added to ocular irrigating solution during cataract surgery or intraocular lens replacement. Phenylephrine is an alpha-1 adrenergic agonist that maintains pupil size by contracting the iris radial muscle. Ketorolac inhibits COX-1 and COX-2 to reduce prostaglandin synthesis, preventing surgically induced miosis and postoperative pain.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Ketorolac Tromethamine, Omidria, OMS302

Drug type

Other

Targets

alpha-1 adrenergic receptor (ADRA1A), cyclooxygenase-1 (PTGS1), cyclooxygenase-2 (PTGS2)

Mechanism

Inhibitor of alpha-1 adrenergic receptor (ADRA1A), cyclooxygenase-1 (PTGS1) and cyclooxygenase-2 (PTGS2)

Pathways

prostaglandin synthesis

Therapy area

Ophthalmology

Developer

Rayner Surgical

In trials of

OMER

FDA status

Approved as Ketorolac Tromethamine, Omidria (May 30, 2014), NDA205388 · FDA label

✅ FDA-approved uses

• Maintaining pupil size by preventing intraoperative miosis (Omidria)
• Reducing postoperative ocular pain (Omidria)

From the indications section of the FDA label (version of Apr 8, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cataract Extraction

Other drugs acting on ADRA1A / PTGS1 / PTGS2

Sources

• FDA label (DailyMed)
• FDA label Omidria (2026-04-08), indications
• FDA label Ketorolac Tromethamine (2024-06-10), indications
• ClinicalTrials.gov NCT00721695
• ClinicalTrials.gov NCT00721695

Updated Oct 3, 2026.